ΕΣΠΑ 2021-2027
Institute of Chemical Biology
ICB

Search

CLOSE
Search
Research / Research Disciplines / Molecular and cellular biology for basic and translational research

Biomarker Discovery: Translational Research

Dr. Theodora Katsila

Group leader
Dr. Theodora KatsilaSenior Researcher
Post-doctoral Research Associates
Dr. Stavroula Gerontogianni2025
Dr. Nastazia Lemonia Lesgidou2025
Scientific Associates
Lydia Galouni2025
Aikaterini Skiada2025
PhD students
Nafsika Rossopoulou2025
Paraskevi Bafiti2021 - 2025
Sotirios Ouzounis2021 - 2025
PhD students (Co-supervisor; Committee member; Vocal)
Marianna Chatzieleftheriou2023 - present
Fotini Perganti2023 - present
Andreas Gkanas2021 - present
MSc students
Michaela Kiralaki, NHRF; NKUA2024 - 2025
MSc students (Co-supervisor; Committee member; Vocal)
Georgios Panagiotou, NHRF; University of Crete2023 - present
Stella Rouvela, NKUA2023 - present
We understand. We harness. We Repurpose. WE GENERATE IP

We understand druggability | safety | translational precision medicine

We harness allostery | molecular + digital biomarkers | chemical space

We repurpose drugs | advanced materials | smart systems

 

Model. Test. Validate. IN3 it

IN3 is a tri-modal innovation engine that fuses in silico, in vitro, and in vivo approaches into a single framework, designed to fast-track safe, effective advanced materials, smart systems and therapeutics from concept to society.

 

IN3 – BIO
Biocompatibility assessment		 IN3 – DRUG
Drug repurposing
Therapeutic Discovery
IN3 – Rx
Clinical pharmacology
NCE/ Drug validation		 IN3 – MED
Systematic NCE/ drug evaluation across modalities
IN3 – OMICS
Multi-omics integration		 IN3 – TOX
Toxicity prediction
Toxicity validation
IN3 – NANO
Nanomaterials
assessment/ repurposing		 IN3 – NEURO
Neurotechnologies
CNS-targeted drug/material pipelines

 

Our IN3 framework also fuels our B2B and B2C ADMETox services. Based on their experience and expertise, the team supports fit for purpose to full compliance.

Mission

Our mission is to fast-track rigorously proven, IP-generating therapeutics and technologies from concept to society while delivering fit-for-purpose ADMETox services for partners across academia and industry.

Vision

We envision a future in which translational precision medicine, next-generation materials, and intelligent systems reach patients and markets faster, safer, and more sustainably than ever before. Driven by our agile IN3 engine, we redefine how discoveries are de-risked, repurposed, and deployed, creating a virtuous cycle of innovation that continuously advaces human health, planetary well-being, and technology.

Major outcomes & achievements

CloudScreen, a “one-stop-shop” next generation computational platform for drug repurposing

CloudScreen, our “one-stop-shop” next generation computational platform for drug repurposing goes beyond existing strategies, as it (a) is not limited to 1D data, but curates/ integrates/ analyzes/ interprets 1D and 3D data coming from molecular design and computational chemistry outputs; (b) minimizes confounding in data mining/ integration/ analysis and promotes unbiased decision-making via the synergy of human and machine (artificial intelligence) reasoning capabilities (i) data mining services, ii) collaboration support services, and iii) decision making services; (c) provides dynamic update capabilities and extends text data services (patents, ethics); and (d) serves as an “one-stop shop” tool for predicting and evaluating the efficacy and toxicity of repurposed biomolecules via ADME-Tox profiling in 3D. This research is supported by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-03153).

  • Bafiti V., Ouzounis S., Siapi E., Grypari I.M., Theofanopoulos A., Panagiotopoulos V., Zolota V., Kardamakis D., Katsila T*. Metabolites, 2023, 13(3):362.
  • Katsila T*, Chasapi SA, Gomez Tamayo JC, Chalikiopoulou C, Siapi E, Moros G, Zoumpoulakis P, Spyroulias GA, Kardamakis D. Cancers, 2021, 13(12):2877.

  • CLOUDSCREEN is one out of the five innovative ideas put forward within the Greek Start-up ecosystem selected by Pfizer. The start4health challenge addresses the Digital Health landscape in shaping the future of health.

  • We were selected to present CLOUDSCREEN: a graph-based drug repurposing platform empowered by machine learning

  • V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis, T. Katsila* EMBO Workshop. The DNA damage response, immunity and aging, Singapore, Singapore. 2022
  • Chalikiopoulou C and Katsila T*. EACR 2022 Congress – Innovative Cancer Science: Translating Biology to Medicine, Seville, Spain. 2022
  • V. Bafiti, V. Panagiotopoulos, M.T. Matsoukas, V. Zolota, D. Kardamakis, T. Katsila*. EACR 2022 Congress – Innovative Cancer Science: Translating Biology to Medicine, Seville, Spain. 2022
  • Chalikiopoulou C., Katsila T*. Targeted proteomics: Experimental design and data analysis, EMBO Practical Course (web event). 2021
  • V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis*, T. Katsila* First ESN-ISN School “From Neurodegeneration to Neural Carcinogenesis: Mechanisms and Common Biologies” [Scholarship to Ms. Bafiti], Athens, Greece. 2021
  • V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis*, T. Katsila* 10th International Conference of the Hellenic Crystallographic Association, Athens, Greece. 2021

Proteogenomics profiling of the 3D cell microenvironment for drug repurposing

We exploit the 3D cell microenvironment via profiling of extracellular vesicles/ exosomes as the means to define the druggable key-players as well as identify and validate candidate companion biomarkers. For this, LC-MSn and high-resolution particle-by-particle 3D fluorescent microscopy measurements are coupled. Extracellular vesicles and exosomes also serve as a toolbox for drug resistance and drug-drug interactions.

  • Highlighted among esteemed colleagues https://www.hupo.org/Humans-of-HUPO/

  • Excited to discuss exosomal metabolomics in health and disease

  • Chalikiopoulou C., Katsila T*. Targeted proteomics: Experimental design and data analysis, EMBO Practical Course (web event). 2021

ADME-Tox in 3D assays and services in a 3-tier strategy; in silico, in vitro, in vivo (EMA CHMP, FDA Guidance for Industry)

Funded by private funders, industry.

  • Kannavou M., Karali K., Katsila T., Siapi E., Marazioti A., Klepetsanis P., Calogeropoulou T., Charalampopoulos I., Antimisiaris S.G. Development and Comparative In Vitro and In Vivo Study of BNN27 Mucoadhesive Liposomes and Nanoemulsions for Nose-to-Brain Delivery. Pharmaceutics, 2023, 15:419.
  • Vachlioti E., Ferikoglou S., Georgiou X., Karampatsis V., Afratis K., Bafiti V., Savard M., Papaioannou D., Katsila T., Gobeil F. Jr, Rassias G. Arch Pharm, 2023, e2200610.
  • T. Rogdakis, D. Charou, A. Latorrata, E. Papadimitriou, A. Tsengenes, C. Athanasiou, M. Papadopoulou, C. Chalikiopoulou, T. Katsila, I. Ramos, K. C. Prousis, R. C. Wade, K. Sidiropoulou, T. Calogeropoulou, A. Gravanis, I. Charalampopoulos. Biomedicines, 2022, 10(3):614.
  • C. Yilmaz, T. Rogdakis, A. Latorrata, E. Thanou, E. Papadimitriou, E. Siapi, K.W. Li, T. Katsila, T. Calogeropoulou, I. Charalampopoulos, V.I. Alexaki. Biomolecules, 2022, 12(3):424.

DeepInhibition

DeepEVision

Monitoring of immunomodulatory mechanisms

We employ multi-omics (LC-MSn) and high-resolution particle-by-particle 3D fluorescent microscopy (extracellular vesicles/ exosomes; nature, number, cargos). The secretome and membrane proteome may add an extra information layer.

  • T. Katsila, M. Juliachs, J. Gregori, T. Macarulla, L. Villarreal, A. Bardelli, C. Torrance, E. Elez, J. Tabernero, J. Villanueva. Clin Cancer Res, 2014, 20: 6346.
  • Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. J Proteome Res, 2014, 13:3706.

  • Fundacio Privada Institut d’Investigacio Oncologica de Vall Hebron, 2014. A method for monitoring the treatment of patients with tumors expressing EGFR. EU WO2015/189106, issued December 17, 2015.

Bioenergetics & Oncometabolism

The accumulation of cell biomass is associated with dramatically increased bioenergetic and biosynthetic demand. Metabolic reprogramming, once thought as an epiphenomenon, currently, relates to tumorigenesis and metastasis, often in response to extracellular fate-decisive signals.

  • Bafiti V., Katsila T.* OMICS, 2022, 26(10): 542-551.
  • A. Poulaki, T. Katsila, S. Giannouli, J.C. Gomez Tamayo, I. Stergiou, A.G. Tzioufas, M. Voulgarelis. Leuk Res, 2021, 108 (suppl1): 106681
  • Poulaki A¥, Katsila T¥, Stergiou IE, Giannouli S, Gόmez-Tamayo JC, Piperaki ET, Kambas K, Dimitrakopoulou A, Patrinos GP, Tzioufas AG, Voulgarelis M. Cancers, 2020, 12(12):3520. ¥1st authorship shared

  • V. Bafiti, V. Panagiotopoulos, M.T. Matsoukas, V. Zolota, D. Kardamakis, T. Katsila* EACR 2022 Congress – Innovative Cancer Science: Translating Biology to Medicine, Seville, Spain. 2022
  • V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis*, T. Katsila* First ESN-ISN School “From Neurodegeneration to Neural Carcinogenesis: Mechanisms and Common Biologies” [Scholarship to Ms. Bafiti], Athens, Greece. 2021
  • Poulaki A, Katsila T, Giannouli S, Gomez-Tamayo JC, Stergiou IE, Tzioufas AG, Voulgarelis M. 16th International Congress on Myelodysplastic Syndromes (web event). 2021
  • Poulaki A, Katsila T, Stergiou IE, Giannouli S, Gomez-Tamayo JC, Kambas K, Patrinos GP, Voulgarelis M. European Hematology Association (EHA) (web event). 2020
  • Katsila T, Poulaki A, Stergiou IE, Giannouli S, Gomez-Tamayo JC, Kambas K, Patrinos GP, Tzioufas AG, Voulgarelis M. 16th Annual Conference, Metabolomics 2020 (web event)

Biomarkers to the Rescue

In-house capabilities are coupled with strategic networks and partnerships for discovery, validation and clinical development of biomarkers.

  • Translational biomarkers (target, mechanism & disease biomarkers) identify the impact of a chemical entity on organs or tissues before a clinical effect is evident.
  • Diagnostic biomarkers (predictive, prognostic & resistance biomarkers) empower patient stratification and enable clinical decisions for potential combinations and/ or next-line therapies. Diagnostic biomarkers maximize therapeutic effects/ minimize ADRs.
  • Pharmacodynamic biomarkers used in pre- and post-treatment settings may shed light to the extent of target modulation, provide biological proof-of-activity, and inform clinical decision making (dosing amounts and/or schedules).
  • Companion diagnostics are intended for launch with a therapeutic drug and enable clinical decision-making (diagnostic or pharmacodynamic biomarker utility)

  • Swen J.J., van der Wouden C.H., Manson L.E., Abdullah-Koolmees H., Blagec K., Blagus T., Böhringer S., Cambon-Thomsen A., Cecchin E., Cheung K.C., Deneer V.H., Dupui M., Ingelman-Sundberg M., Jonsson S., Joefield-Roka C., Just K.S., Karlsson M.O., Konta L., Koopmann R., Kriek M., Lehr T., Mitropoulou C., Rial-Sebbag E., Rollinson V., Roncato R., Samwald M., Schaeffeler E., Skokou M., Schwab M., Steinberger D., Stingl J.C., Tremmel R., Turner R.M., van Rhenen M.H., Dávila Fajardo C.L., Dolžan V., Patrinos G.P., Pirmohamed M., Sunder-Plassmann G., Toffoli G., Guchelaar H.J.; Ubiquitous Pharmacogenomics Consortium. Lancet, 2023, 401(10374): 347
  • Kumuthini J, Zick B, Balasopoulou A, Chalikiopoulou C, Dandara C, El-Kamah G, Findley L, Katsila T, Li R, Maceda EB, Monye H, Rada G, Thong MK, Wanigasekera T, Kennel H, Marimuthu V; G2MC Evidence investigators, Williams MS, Al-Mulla F, Abramowicz M. Hum Genet, 2022, 141:1697
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Clin Cancer Res, 2014, 20:6346

From genotype-to-phenotype associations toward the clinical interpretome

The team focus is on contextual data, data reliability and interpretation. An artificial-human intelligence workspace facilitates data mining and curation to empower data reliability and reproducibility.

This is an illustration of an active synergistic workspace in which multi-faceted data derived from diverse and distributed sources is mined and interrogated. Interoperability is facilitated by the same synergy of human and artificial intelligence which is also anticipated to diminish biases. Nodes may represent ideas, comments, notes, services, data. Lines represent network interactions; those in light blue are those that exhibit evidence-based dominance, those in red are those that fail, while those in dark blue are the ones to be re-visited. In such a way, contextual data integration results in an evidence-based dominant outcome (node in red). Contextual or out-of- context data are equally re-visited and interrogated, and they will only survive, if evidence-based.

  • V. Bafiti, S. Ouzounis, C. Chalikiopoulou, E. Grigorakou, I.M. Grypari, G. Gregoriou, A. Theofanopoulos, V. Panagiotopoulos, E. Prodromidi, D. Kavouras, V. Zolota, D. Kardamakis, T. Katsila*. Curr Oncol, 2022, 29(6), 4351
  • Jenko Bizjan B, Katsila T, Tesovnik T, Šket R, Debeljak M, Matsoukas MT, Kovač J. Comput Struct Biotechnol J, 2019, 18:83
  • Katsila and Matsoukas, 2018, Expert Opin Drug Discov, 13:791

A Robust Machine Learning Framework Built Upon Molecular Representations Predicts CYP450 Inhibition: Toward Precision in Drug Repurposing

Sotiris Ouzounis†, Vasilis Panagiotopoulos, Vivi Bafiti, Panagiotis Zoumpoulakis, Dionisis Cavouras, Ioannis Kalatzis, Minos-Timotheos Matsoukas, and Theodora Katsila
OMICS: A Journal of Integrative Biology 27, no. 7 (July 2023): 305–314
https://doi.org/10.1089/omi.2023.0075

Technology Transfer

  • CLOUDPHARM PC. NHRF, 2024. Application Number N2039646
  • CLOUDPHARM PC. NHRF, 2024. Application Number N2039647
  • CLOUDPHARM PC. NHRF, 2024. Application Number N2039645
  • CLOUDPHARM PC. NHRF, 2024. Application Number N2039644
  • Fundacio Privada Institut d’Investigacio Oncologica de Vall Hebron, 2014. EU WO2015/189106, issued December 17, 2015.

 Micro & Nano Scientific Society
2025
Hellenic Society for Extracellular Vesicles
2025
International Society for Extracellular Vesicles.
2024 – present
Imaging Mass Spectrometry Society (IMSS)
2023 – present
Universal Scientific Education & Research Network.
2023 – present
European Radiation Research Society
2022 – present
European Society of the History of Oncology
2021 – present
Females in Mass Spectrometry (FeMS)
2020 – present
Metabolomics Society
2020 – present
European Association of Systems Medicine (EAsyM).
2018 – present
Open Technologies Alliance (GFOSS)
2018 – present
Human Proteome Organization (HUPO)
2016 – present
Global Genomic Medicine Collaborative (G2MC).
2016 – present
European Association for Cancer Research (EACR).
2012 – present
Association of Greek Chemists.
2011 – present
Member of A. G. Leventis Foundation Scholars Association Board (Greece).
2007 – 2011
Full Member of the Hellenic Society of Biochemistry/ Molecular Biology.
2005 – present
Associate of the Royal College of Science (RCS) Association. 2004 – present
Member of the Imperial College London Alumni Association. 2004 – present

2024-2028. HORIZON EUROPE. EU INFRATECH. “Multi-domain Open MALDI Spectra BANK for Identification of Microorganisms (MALDIBANK)”.
Total budget: 10,000,000.00 €. Role: Partner
2024-2028. HORIZON EUROPE. “The Environmental Exposome and Health (ENVESOME)”.
Total budget: 386,250.00 €. Role: Partner
2024-2025. ADME-Tox services. Private funding, Industry. Budget: 60,000.00 €. Role: PI
2023-2027. HORIZON EUROPE – KDT Research & Innovation Actions. Project title: “Intelligent neural system for bidirectional connection with exoprostheses and exoskeletons (NerveRepack)”. Total budget: 15,575,733.75 €. Lab budget: 400,000.00 €. Role: Partner
2023-2024. Partnership for Advanced Computing in Europe. Project title: “DeepEVision: An end-to-end deep learning framework for the fully automated annotation, quantification, and characterization of extracellular vesicles in transmission electron microscopy images”. Role: PI
2023. European High-Performance Computing Joint Undertaking. Project title: “DeepInhibition: IC50 prediction through ligand-receptor pairs interactions”.Role: PI
2022-2026. COST Action CA21153. Project title: “Network for implementing multiomic approaches in atherosclerotic cardiovascular disease prevention and research (AtheroNET)”. Role: Partner
2022-2026. COST Action CA21135. Project title: “Modelling immunotherapy response and toxicity in cancer (IMMUNO-model)”. Role: Partner
2022. HPC-GRNET. Project title: “Extending 3D Drug Repurposing predictions to the human Variome and extended (AlphaFold) Proteome space”. Role: PI
2021. EPIC-XS Grant. EPIC-XS project 371. Project title: “An integrated model to gain mechanistic insights in glioblastoma prognosis”. Budget: 20,532.00 €. Role: PI
2021-2025. ADME-Tox services. Private funding, Industry. Budget: 25,000.00 €. Role: PI
2021-2025. ADME-Tox services. Private funding, Industry. Budget: 22,070.90 €. Role: PI
2020-2023. National Strategic Reference Framework 2014-2020. General Secretariat of Research and Technology-Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-03153). Project title: “CLOUDSCREEN”. Total budget: 469,791.88 €. Lab budget: 352,561.98 €. Role: PI
https://cloudscreen.gr/?lang=en
2020-2023. National Strategic Reference Framework 2014-2020. General Secretariat of Research and Technology – Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-03847). Project title: “Design and development of a novel food supplement for osteoporosis based on gut microbiome mechanisms. Efficacy and tolerability assessment”. Total budget: 952,080.00 €. Lab budget: 62,760.00 €. Role: Partner
https://osteome.eu/?page_id=40
2020-2022. State Scholarships Foundation (IKY). Operational Programme «Human Resources Development, Education and Lifelong Learning» in the context of the project “Reinforcement of Postdoctoral Researchers – 2nd Cycle” (MIS-5033021). Post-doctoral research fellow: Dr. Angeliki Balasopoulou. Total budget: 26,400.00 €. Lab budget: 26,400.00 €. Role: Coordinator
2020. HPC-3 Europa Transnational Access Grant.
Project code: HPC17B9U3T. Role: PI
2016-2017. Private funding, Industry.
Budget: 22,000.00 £. Role: PI

For a complete list of my peer-reviewed research publications, please visit:

https://www.scopus.com/authid/detail.uri?authorId=24066813500

  • 88th Thessaloniki International Fair
    NerveRepack was showcased at the 88th TIF by National Hellenic Research Foundation (NHRF). N. Rossopoulou and Chr. Fragkou, members of the NHRF team led by Dr. Theodora Katsila, presented the project and the role of their team in WP7 (new materials and biocompatibility).
    With more than 1300 exhibitors, 32,000 square meters of exhibition space, Germany as the Honoured Country with 135 enterprises and institutions, 25 international state participations, nine thematic events, and the dynamic presence of the Chambers of Greece with 350 companies from all over Greece under the auspices of the UHC, the 88th TIF conveyed a strong message of development and international cooperation. More about TIF 2024: https://thessalonikifair.gr/en
    https://shorturl.at/olvF3; https://shorturl.at/ewaC2; https://shorturl.at/TQYTh
  • Financial Grant in Memory of Miltiadis Empirikos (Empirikeio Foundation)
    https://rb.gy/3uonub
  • TRANSCAN December 2024 newsletter
    TRANSCAN-3 network held its 2nd Symposium in Catania, Italy. All participants in projects funded under the JTC 2022 call “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy” were invited to this event, where they had the chance to share their progress and latest results as well as lessons learned in the first months of their joint work. The event counted with the presence (on site and online) of almost 70 participants from over 30 countries. The session was chaired by T. Katsila and Tr. Liloglou, former members of the scientific evaluation committee that evaluated the JTC 2022 projects. The presentations were a great chance for the researchers to learn about each other’s projects and to establish new collaborations and allowed funding agencies to gain first-hand insights into the progress of the funded actions. More about TRANSCAN: https://shorturl.at/RXk2
  • Annual Rosalind Franklin Society Award in Science
    The 2023 Rosalind Franklin Society (RFS) Awards in Science in partnership with Mary Ann Liebert Inc. recognize outstanding peer-reviewed research by women and underrepresented minorities in STEM. More about 2023 RFS Awards: https://www.rosalindfranklinsociety.org/rfs-awards-in-science-2023; https://shorturl.at/9X4o3; https://rb.gy/j1y316; https://rb.gy/7qco37
  • Remarkable HUPO volunteer (Human Proteome Organization)
    HUPO highlights volunteers who lead and support many of HUPO’s various Committees, Initiatives and Working Groups. More about HUPO: https://rb.gy/v0e7zd
  • Humans of HUPO (Human Proteome Organization)
    HUPO highlights a member of HUPO. This initiative improves visibility of HUPO members, advertise research and enhance the HUPO community. More about HUPO: https://www.hupo.org/Humans-of-HUPO/
  • 86th Thessaloniki International Fair
    The Biomarker Discovery & Translational Research Laboratory at NHRF led by Dr. T. Katsila presented NanoSpot.ai. A SARS-CoV-2 IgG/IgM Rapid Test that quickly and reliably detects the presence of antibodies against the receptor binding domain of the viral spike protein (Spike-RBD) of SARS-CoV-2 by hemagglutination. Image processing and data analysis are performed by AI algorithms. NanoSpot.ai™ technology is innovative being an AI-driven point-of-care diagnostic tool. Thanks to the catalytic and close collaboration of the ICHB/NHRF (Biomarker Discovery Laboratory: Translational Research) and ATHROA INNOVATION IKE, Opto (“OPTO IMMUNOSENSORS IKE”, a subsidiary of Uni-Pharma and ATHROA INNOVATION IKE) intends to develop future and more innovative products from inventions of researchers in and outside Greece in the emerging sector of Connected Diagnostics (“Connected Diagnostics”). More about TIF 2022:https://shorturl.at/09Atm; https://shorturl.at/A8Q9v; https://shorturl.at/WJWZ8
  • Pre-validation and ADME-Tox studies of the Photostick immunosensing system
    As a concept, the Photostick immunosensing platform was born in an effort to create a versatile and ubiquitous immunodiagnostic point-of-care diagnostic that exploits the analytical power of light, but is not compromised by operational complexity, increased cost and volume. Photostick was based on the need to move the lab to the field and offer affordable but accurate, de-centralized mass-testing. The Biomarker Discovery & Translational Research laboratory participated in a double-blind test study measuring independently and sequentially the same set of samples. More about Photostick: https://shorturl.at/UQAZb
  • Interview of the Associate Researcher of the Institute of the Chemical Biology (ICB), Dr. Theodora Katsila Please visit: https://shorturl.at/UQAZb
  • Descubren un marcador para monitorizar el cáncer colorrectal con muestras de sangre. EQUIPO DEL VHIO BARCELONA, 30 Oct. (EUROPA PRESS) – Investigadores del Vall d’Hebron Instituto de Oncología (VHIO) han descubierto un marcador que permitirá monitorizar el tratamiento del cáncer colorrectal a través de muestras de sangre, lo que supone un nuevo método práctico y no invasivo. More about CRC biomarker: https://shorturl.at/cQXCv
  • La sangre revela si el tratamiento del cáncer de colon es efectivo
    Viernes, 31 de octubre del 2014. Científicos del Hospital Vall d’Hebron de Barcelona han descubierto un nuevo marcador que permite comprobar si el tratamiento del cáncer colorrectal que recibe un paciente es efectivo o no mediante un simple análisis de sangre. More about CRC biomarker: https://shorturl.at/YWieg
Group leader
Dr. Theodora KatsilaSenior Researcher
Post-doctoral Research Associates
Dr. Stavroula Gerontogianni2025
Dr. Nastazia Lemonia Lesgidou2025
Scientific Associates
Lydia Galouni2025
Aikaterini Skiada2025
PhD students
Nafsika Rossopoulou2025
Paraskevi Bafiti2021 - 2025
Sotirios Ouzounis2021 - 2025
PhD students (Co-supervisor; Committee member; Vocal)
Marianna Chatzieleftheriou2023 - present
Fotini Perganti2023 - present
Andreas Gkanas2021 - present
MSc students
Michaela Kiralaki, NHRF; NKUA2024 - 2025
MSc students (Co-supervisor; Committee member; Vocal)
Georgios Panagiotou, NHRF; University of Crete2023 - present
Stella Rouvela, NKUA2023 - present
Information & Contact
Dr. Theodora Katsila
Senior Researcher
+30 2107273752